At RM Laboratory, Yeshiva University, I authored the research plan for a study of stress-granule-mediated resistance to PRMT5 inhibition and won an institutional grant to fund it. I also designed an eight-arm combination study and presented research on PRMT5 inhibition in KRAS-mutant colorectal cancer at AACR 2026.
At Frezent Biological Solutions, I evaluated AI and computational-biology vendors for an oncology modeling platform and recommended an in-house build using PhysiCell; the CEO adopted the recommendation. I also developed GMP-aligned quality-control documentation for preclinical studies and delivered a phased implementation roadmap with a clickable dashboard prototype.
